GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and TPI Enterprises want the government of Australia to let them grow poppies on the country's mainland, due to a shortage of opium for pain killers and amid soaring demand.
GlaxoSmithKline is also constantly improving this segment and allocated around $6 billion in research and development in the last year, a greater portion of R&D expenditure is devoted to the pharmaceutical division.
GlaxoSmithKline (GSK -0.7%) submits its supplemental new drug application ((sNDA)) for its drug Promacta for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anemia (SAA), a disease characterized by the failure ...
With the recent approvals of two inhaled products, Breo Ellipta and Anoro Ellipta, GSK is now aiming to gain market share for chronic obstructive pulmonary disease (COPD), which is expected to grow to a $16 billion market by 2020.
GlaxoSmithKline plc (ADR)(GSK)creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide.
... obstructive pulmonary disease (COPD), according to GlaxoSmithKline plc (ADR) (NYSE:GSK). GlaxoSmithKline plc (ADR) (NYSE:GSK) stock opened at $56.23 in last session, and closed at $55.69, while the day range of GSK stock is $55.65 - $56.28.